BLOOM4³

PLEXaa Limited, based in London, UK, and founded in 2020, specializes in medical devices that enhance patients' pre-surgical preparations to minimize complications and improve recovery outcomes. PLEXaa Limited develops innovative medical technology aimed at improving surgical outcomes. The company is headquartered in London, UK. The founder, whose past entrepreneurial experiences are not disclosed, led the firm to secure USD 4.

5 mn in Seed funding from TCP Health Ventures and Thena Capital in July 2025. This funding is part of a total raised amount of USD 4. 5 mn. PLEXaa Limited offers the BLOOM⁴³ device, which utilizes supraphysiological preconditioning™ to boost natural healing prior to surgery.

Designed for patients facing surgical procedures, BLOOM⁴³ increases blood flow to enhance physiological readiness, targeting healthcare practitioners and institutions in North America and Europe. The revenue model for PLEXaa Limited comprises direct-to-consumer sales alongside partnerships with healthcare providers. Transactions may include individual device purchases or subscription services via the BLOOM⁴³ app, with options for bulk orders from healthcare facilities to support patient care initiatives. Following the recent Seed funding of USD 4.

5 mn secured in July 2025, PLEXaa Limited plans to launch BLOOM⁴³ in the U. S. market while setting the stage for future innovations. The funding will also support preparations for an anticipated Series A fundraising round.